(Vax-Before-Travel News)
The only protein-based, non-mRNA COVID-19 vaccine produced in the United States will continue to be available in Japan, the world’s third-largest pharmaceutical market.
Novavax, Inc., announced on May 5, 2025, that it has updated the terms of the previously announced collaboration and licensing agreement with Takeda, a pharmaceutical firm located in Osaka, Japan.
“Our ongoing partnership with Takeda is important for Novavax, and our strengthened agreement enhances our ability to operate effectively in the Japanese market,” said John C. Jacobs, President and CEO of Novavax, in a press release.
“This partnership further validates our cutting-edge technology platform and proprietary Matrix-M® adjuvant and our efforts to become a partner of choice.”
The improved financial terms of the amended agreement for the development, manufacturing, and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 season, annual milestones associated with regulatory approvals, and royalties on net sales earned every season moving forward.
Since the World Health Organization granted an Emergency Use Listing for Novavax’s earlier COVID-19 vaccine version in December 2021, numerous countries, including the United States, have authorized its use.
Novavax’s vaccines are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis.
AloJapan.com